Good morning all. It's been years since I've posted but have been invested in BIEL since 2009. This certainly does feel different than the numerous times over the years where the stock price quickly spikes on either rumors or a PR, just to drop precipitously. I'm encouraged at the foundation that the management team has been building and the progress to date. For all of us Longs out there, let's keep our fingers crossed for continued better days ahead!

I agree! As much as I would love to have seen the stock price continue to climb, I'm actually pleased to see the relatively sideways trading and stability over the last several days (since the dramatic rise, drop, and recovery). I've watched so many times in the past 9 years of the stock spiking up briefly, but never being able to hold any sort of gains made and dropping back to very low levels.

There are so many positive factors in-play and on the horizon, and it's great to see the stock price holding ground as a result, waiting for the next exciting development!

Just FYI, I received exactly the same email from Chris following my original email to Paul inquiring about the communication (I did not however hear back from Paul directly).

Yes, I did as well. I'm not sure quite what to make of that. Is there any significance?

Hi everyone. I've been a BIEL shareholder since my first purchase at about 6 cents/share back in about 2009. I've averaged down over the years but only to about $.0045, so it's very exciting for me to actually approach a break-even point! What has kept me hanging in there for all of these years is that I believe in the technology, the product, and the company (although like most I can't say that I've agreed with all of their decisions over the years). I admire both the company's perseverance and that of all of us "Longs" out there! It's really gratifying to see all of the positive developments and the potentially bright future ahead, and I want to say a big THANK YOU to all of the knowledgeable posters out there that have provided great insights over the years. I don't post often, but I read posts almost everyday. GO BIEL!

BioElectronics Appoints Southeast Asia Distributor
FREDERICK, Md., BioElectronics Corporation (OTC Pink: BIEL), November 1st 8:30 AM, the maker of advanced consumer pain management medical devices, today announced that it has appointed PharmEvo https://www.pharmevo.biz as its ActiPatch® Musculoskeletal Pain Therapy distributor for Vietnam, Kenya, Cambodia, Myanmar, Kenya and Sri Lanka.

PharmEvo was established in 1999, has a sales team of 850 people, and annual sales of over $300 million. Corporate headquarters are in Karachi, Pakistan with 9 locations in Pakistan and international market coverage in Vietnam, Cambodia, Kenya, Philippines, Myanmar, Sri Lanka Guatemala, Kenya Tanzania, Pakistan, Kazakhstan, and Uzbekistan. PharmEvo engaged in the creation, development, manufacture and marketing of pharmaceutical products, including over-the-counter (OTC) medicines, medical equipment and infant formulas. PharmEvo partners with following international groups for bringing best quality products to its consumers, Bioton (Poland), Lactalis (France), Omron (Japan), Becton Dickson (USA), etc.

Nadeem Rehmat, Director of PharmaEvo Business Development has expressed his confidence that ActiPatch Musculoskeletal drug-free inexpensive pain therapy is a great fit to their OTC line.
“We are pleased to have PharmEvo selling our ActiPatch products in Southeast Asia.” We believe our unique cost effective drug-free pain therapy will have excellent market acceptance in Asia,” said Erin Sanders, BioElectronics Sales Manager.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic wounds and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.

Contact:
Grace Holdings, Inc.
732-335-1152

Release #:812-161653-rl-799290:
BioElectronics Update

Pending U.S. FDA Market Clearance for Over-the-Counter Sales

We had a second status meeting with the FDA on Wednesday, July 20, 2016. Senior Management from the Neurology and Physical Medicine Group, 4 examiners, the Head of the Physical Medicine, and the project statistician were present. The meeting went well and the tenor was very good.


They have accepted our knee and plantar fasciitis studies as indicative of musculoskeletal pain relief and our explanation of our unique mechanism of action. However, they would like a third study to substantiate our broader indication of use. To accommodate our request for market clearance for the relief of musculoskeletal pain, the examiners have agreed to exclusively review the back pain data from our UK Registry studies. Some of this data is peer reviewed and published. We have approximately 4,500 subject’s responses, who used the trial device for musculoskeletal back pain, as well as data on over 100 subjects demonstrating the durability of therapy over a 6 month study period for back pain.

BioElectronics Corporation Refutes SEC Order for Administrative Proceedings


[08-February-2016]

FREDERICK, Md., Feb. 8, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced today that it is responding to a notice of an order for administrative proceedings from the Securities and Exchange Commission posted on the agency website.
"Although neither the Company nor any of the respondents have been formerly served, we have reviewed the allegations on the website. We want our shareholders to know that we consider the SEC position to be without merit or foundation in fact," said Richard Staelin, Chairman of the Board of BioElectronics Corporation and the Edward and Rose Donnell Professor of Business Administration at The Fuqua School of Business, Duke University.
Staelin explained that the SEC's document contains numerous factual errors and boils down to two issues, both of which have been disclosed previously to BioElectronics shareholders. These issues are:
Revenue recognition for two sales in 2009. Both sales were final and paid in full. Independent SEC-reporting consultants prepared the Company's financial statements and an independent, 225-person audit firm audited the transactions and determined they met the criteria required to recognize the revenue in the audit report and in the SEC filed 10k. The transactions are not a question of income recognition but an issue of when to record the sales.
Use of convertible shareowner loans to fund the Company. As fully disclosed in Company financials, BioElectronics has financed its development operations in part with convertible loans.
It appears that the SEC objects to the Whelans sale of some of its loans to different individuals and entities. All note sales were to qualified investors in accordance with SEC Rule 144 and held for longer than the SEC mandated holding period. The sales were fully disclosed and reviewed by legal and accounting advisors. The Whelans reinvested the proceeds of the loans in the Company, which represents only $1 for every $2.60 of their additional $5.6 million loans to the Company since 2010. It is not clear in the complaint if the SEC objects to shareholder sales or investing the proceeds in the Company.
Staelin also said that BioElectronics has filed with the SEC on two occasions and was stymied by administrative requirements that were not affordable by a small company. "We are confident that the Company and the respondents identified (including the head auditor) will be vindicated," Staelin concluded.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-corporation-refutes-sec-order-for-administrative-proceedings-300216474.html
SOURCE BioElectronics Corporation

FYI, Paul Knopick responded that the Company will be issuing a PR related to this issue.

Here is a copy of the press release:

BioElectronics Applauds Important FDA Ruling

BioElectronics Applauds the FDA's Reclassification of Nonthermal Shortwave Therapy Devices


[14-October-2015]



FREDERICK, Md., Oct. 14, 2015 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), maker of consumer medical electronics products for pain management endorsed the U.S. Food and Drug Administration's final rule 890.5290 on nonthermal pulsed shortwave devices published today in the Federal Register.

"I am pleased the agency has completed this step in streamlining the regulatory requirements for making available to Americans, the same safe drug-free pain relief option enjoyed in other countries around the world," said Andrew J. Whelan, President. Earlier this year, in response to our request for information regarding the regulatory status of ActiPatch®, the FDA confirmed that it falls within the classification regulation that is the subject of the reclassification. We believe that the reclassification will contribute to an efficient review of our submitted evidence in our 510(k) premarket notification. The reclassification to Class II includes a provision for the FDA's evaluation of our request for over-the-counter market clearance.

The Company is confident that the need for a safe, effective, and affordable drug-free treatment for chronic pain, without the dangers of narcotic and non-steroidal anti-inflammatory drugs, will further encourage swift FDA action.

Complete text of the FDA filing is available:
https://www.federalregister.gov/articles/2015/10/13/2015-25923/physical-medicine-devices-reclassification-of-shortwave-diathermy-for-all-other-uses-henceforth-to

About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.

Contact:
BioElectronics
Paul Knopick
940.262.3584
pknopick@eandecommunications.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-applauds-the-fdas-reclassification-of-nonthermal-shortwave-therapy-devices-300159326.html

SOURCE BioElectronics Corporation

Thanks seven-up!

Thanks for posting that believer. Hopefully anyone seeking to learn more will now see where to go look!

Does anyone know why Simpsonly's post #56111 appears to have been deleted? As many here have stated, it was an outstanding summary and would be extremely valuable reading for those less familiar with BIEL. With the great news and activity yesterday, I bet that there will be many people seeking just this kind of information over the weekend and into next week. It makes zero sense why this post would have been deleted while the constant barrage of negative post from paid bashers does not!

I just received this email from E & E Communications:

Release #:812-155559-em-1189392:
BioElectronics Announces FDA Actions

BioElectronics (BIEL) today asked us to share this important announcement from the U.S. FDA with its investors:



https://www.federalregister.gov/articles/2015/10/13/2015-25923/medical-devices-physical-medicine-devices-shortwave-diathermy-for-all-other-uses-henceforth-to-be


Paul Knopick

Thanks for the update. I tried to join in on the streaming interview but for some reason I'm not able to connect. Any updates on the content afterwards would be appreciated!

Looks like there have been two very large buys already this morning. It will be interesting to see if this is isolated or the start of increased activity?

Very interesting investor release this morning:


Release #:812-147307-em-799290:
BioElectronics Investors: Interesting Article for Our Future

Thursday, December 11, 2014

WEALTH WISDOM

Electrical pulses could replace many traditional medicines

-- New Frontier In Medical Science --

Imagine a world in which health disorders could be treated by an implantable device that “speaks” the electronic language of the body. Signals travelling along the nervous system could be analyzed for abnormalities, and corrected to treat conditions as diverse as arthritis, asthma, diabetes and, perhaps one day, even cancer. It sounds like science fiction but a growing number of scientists believe the concept can work.

This, in turn, is rousing interest from pharmaceuticals companies, alerted to both the opportunities and the risk of disruption from technologies that could one day make many traditional medicines obsolete.


GlaxoSmithKline has been most aggressive so far, setting up a $50 million venture capital fund to “invest in companies that pioneer bioelectronic medicines and technologies." “The nervous system is a fundamental control system in biology,” says Kristoffer Famm, GSK’s head of bioelectronics R&D. “Over the long term we’re betting that this is not going to be just two or three types of treatment, it is going to be a whole new class of therapeutics.”


In some respects, bioelectronics is not as futuristic as it sounds. Scientists and medics have been experimenting with the idea since Australian doctors revived a stillborn baby in a Sydney hospital in 1928 by inserting an electric-charged needle into the heart. This was the genesis of the modern pacemaker that today regulates the heartbeat of four million people around the world. But the new generation of bioelectronics, or “electroceuticals”, would go much further. GSK says it believes the technology “could allow us to address some diseases that have so far been untreatable, and others with greater precision and fewer side effects than with conventional medicines."

GSK has invested in a US company called SetPoint Medical, which is developing a tiny implantable device that stimulates the vagus nerve in the neck with electronic pulses. This is intended to counter the inflammation behind rheumatoid arthritis and Crohn’s disease. Clinical trials are under way.
The vagus nerve is a focus of bioelectronic research because of its wide reach around the body. A New Jersey-based company called electroCore is exploring ways to treat conditions ranging from respiratory to gastrointestinal complaints by tapping into this neural superhighway.

While GSK and SetPoint believe implantable devices are necessary to maximize proximity to the nerve during stimulation, electroCore thinks treatments can be delivered through the skin. Its handheld gammaCore device treats migraine headaches using electronic pulses to the neck. Stimulating the vagus nerve helps control glutamate, a substance that has been linked with migraines.

JP Errico, electroCore’s founder and chief executive, says such treatments could in future be downloaded from “virtual pharmacies” and delivered from a smartphone. Regulators are taking bioelectronics seriously. In May, the US Food and Drug Administration approved a device by Inspire Medical Systems that treats sleep apnea by stimulating the airway muscles. A month later, an FDA panel recommended a weight-control device from EnteroMedics that stimulates the vagus nerve to make a person feel full.
Evangelists believe this is just the start. The long-term aim is to decode the blizzard of signals from the body’s millions of neurons to identify and correct malfunctions.

GSK has offered a $1 million prize to the first scientists to create “a miniaturized, fully implantable device that can read, write and block the body’s electrical signals to treat disease."

Some see bioelectronics as a step towards a “human enhancement” revolution in which biology, computing and robotics merge. Breakthroughs in the so-called “brain-computer interface” has already allowed paralyzed people to move mind-controlled robotic arms.
Talk of cyborgs and bionics is likely to breed as much skepticism as excitement in the conservative world of big pharma. But companies such as SetPoint and electroCore insist they are building the evidence to show that bioelectronics has a chance of becoming a new frontier in medical science.

Latest Investor Update released early today:

http://www.bielcorp.com/investors/investor-updates/

Just a note of thanks:
Hi everyone. As with many of you, I have been a shareholder and advocate of BIEL since '09. I made the common mistake of buying-in near the high point, but have been adding to my holdings ever since and have averaged down to just less than one cent (still at a large deficit at this point of course). I read the postings on this site daily and have only posted a few times over the years; primarily because I don't have a lot of insight to add where it already hasn't been covered by others. My family and I have used Actipatch on several occasions and I am a true believer in this product and company, and the potential value that it can/will bring to the U.S.

My point for writing today is just to give a big "Thanks" to all of you that have so diligently posted and shared your thoughts, research and insight for all of these years. I truly appreciate your efforts here, as I'm sure many others do as well. This is an exciting time to be a BIEL shareholder. After being so engaged in Bioelectronics now for 5 years, it's hard to imagine a day in the future when I'm not so invested in this company, closely watching it, and reading all of your posts! I will probably continue to hold at least some portion of my shares even after the PPS has climbed dramatically and I've recouped my investment. So thank you all for your continued contributions to this forum!

Thanks for the information uksausage. I also just received (as did most of you I expect) this email from E&E Communications:

BioElectronics (BIEL)


For those inquiring about lack of trading of BIEL today:

From: Issuer Services [mailto:issuers@otcmarkets.com]
Sent: Thursday, November 07, 2013 9:54 AM
To: Issuer Services
Subject: OTCIQ Outage – 11/7/2013



Dear Subscriber,



Otciq.com is currently unavailable. We are working to rectify the problem and hope to have the service up shortly. Updates will be provided as they become available.



Regards,



Issuer Services

It seems unusual to have zero trading activity at this point in the day. Does anyone know of a reason for this, or is it just an unusually quiet trading day? Thanks for sharing any insight.

FYI, I was able to exchange emails with Paul K. this morning, and he said that there will be a President's letter published soon to explain the current situation.

If you look on the bielcorp.com website, the next investor update is scheduled for Jan 3.
Next Investor Update: Thursday, January 03, 2013

Investor Update is out:

BioElectronics Corporate Update


BioElectronics Investor Update – Thursday, July 26, 2012



SPAIN



Our distributor in Spain, Palex Medical (www.palexmedical.com), with a long record of success as experts in distributing medical technology in that European nation that has a growing population exceeding 45 million, has made its first order for BIEL products and they will be shipped next week. This follows an extensive market research study of our products and the Spanish market conducted by an independent research group. “We anticipate seeing our products on the shelves in key retail places in Spain by this Fall,” said Andrew Whelan, President.





VENEZUELAN



“We have emphasized repeatedly that we are not simply going to sit waiting impatiently for the U.S. FDA to make decisions on our products, but that we are going to seek out the best distributors all over the world and sign them up for international sales,” Mr. Whelan said. “We are pleased to announce that Comercializadora Almed, a distributor of medical and surgical products for pain and treatment supplies for operating room procedures. Comercializadora Almed is also a distributor for Johnson & Johnson products in South America.





FIME Trade Show



BioElectronics will be attending the 2012 FIME Trade Show in Miami Beach, FL August 8-10. FIME is the largest International Medical Trade Fair and Congress in the United States. The annual event is a purchasing show drawing conventional distributor networks, group purchasing organizations, integrated delivery networks, hospitals, imaging centers, private practice facilities, and HME / DME providers. Attendees visit FIME to see the latest medical equipment, products, supplies, technology and services and learn from industry experts in the three day, six track educational conference.



“We re excited by the opportunity and look forward to making important, new contacts for BIEL,” said Ben Fichter, Marketing, BIEL.





http://www.fimeshow.com/Fime_web_2012.pdf



http://www.fimeshow.com/

Investor Update is Out:

BioElectronics Investor Update


BioElectronics Investor Update – Thursday, June 21, 2012




INDIA

Juno Pharmaceuticals – Medical Division, is an interesting company formed in 2011 by a Canadian venture fund and developed and funded by experienced pharmaceutical executives. Juno is committed to bringing reliable, long-lasting and quality products from the world over to cater to medical specialists, institutions, distributors and associates with particular focus on opportunities in Asia, Africa and Asia Pacific.

Juno Pharmaceuticals has launched an Ecommerce website at http://www.actipatch.in, which is now accepting orders for BIEL’s ActiPatch® pain relief devices. Juno is announcing an aggressive marketing campaign designed to reach the growing middle class in India. Juno has reported that medical professionals who have used the product report positive results. Visit Juno on Facebook: http://www.facebook.com/junopharm or follow them on Twitter: https://twitter.com/junopharminc.

Senator Mikulski

The management and Board of Directors deeply appreciate the assistance and efforts of Senator Barbara Mikulski and her staff. Senator Mikulski forwarded us the FDA’s response to her inquiries on BioElectronics Corporation’s behalf. You may review both letters here: http://bielcorp.com/wp-content/uploads/2012/06/Barbara-Mikulski-Letter-to-BIEL-6-14-12.pdf

FDA

Allay

We were pleased with the Friday, June 8, meeting with the FDA. At the meeting we addressed the application of the technology to support our menstrual pain medical claim for Allay.

Dr. Kenneth McLeod, our consulting biophysics expert, made the technical presentation. Dr. McLeod received his PhD from MIT in electrical engineering, with a dissertation focused on electrophysiological properties of living tissue, and has worked in the field of bioelectromagnetics for more than 30 years. He is currently Director of the Clinical Science and Engineering Research Center at Binghamton University where the research is largely focused on functional disorders (such as chronic pain) and interventions to address these disorders. BioElectronics’ Chairman, Dr. Richard Staelin, is a mathematician and statistician, and was in attendance to support the clinical data analysis. Andrew Whelan was also in attendance at the meeting.

RecoveryRx

We have a teleconference meeting with the FDA in July regarding our RecoveryRX™ post-surgical product.

ActiPatch

Our request for over-the-counter classification of the ActiPatch products is going through final review and concurrence processes.

I have never had a problem buying through Schwab (although my last purchase was approximately 2 months ago).

Not sure if anyone else encountered this problem yesterday. I had tried several times to submit an email to Senator Mikulski using the link that fuja21 had provided. Every time that I submitted it said that the site was experiencing problems and it was not successful. However, when I tried again this evening it went through successfully on the first attempt. Thought I would pass this along to the board in the event others had the same problem yesterday. Good luck to all and I do hope the Senator receives a large volume of messages!

FYI, I received that same Marketing Summary late last night from E&E Communications. I had assumed that it was a follow-on to the earlier investor update and that I received it because I am on their investor mailing list. Curious though if several of you did not receive it? I looked on bielcorp.com earlier today and did not see it on their investor update page either.

It came from: From: "E & E Communications <pknopick@eandecommunications.com>" <admin@investorpass.com>

FYI regarding my recent attempt to purchase an Acti-patch back patch through Amazon. I placed an order for one unit on Feb. 15th, and received a shipping confirmation email on Feb 16th, with a UPS tracking number. When I click on the "track your package" link, the estimated arrival is "Not available" and status is "out for delivery". Apparently I was able to place the order before the restrictions were put in place, but now the order has been apparently cancelled (although I have received no confirmation notice of this). Thought I would share this for some additional information to the forum.

I wasn't happy about the lack of progress reported in the Investor Update regarding the Canadian retail launch, but I actually was pleased to see them being more forthcoming on the reasons for the delay. This was the first that I recall hearing about the retailers' annual review of product placement on shelves and that this review is due to occur in the next few weeks with Shoppers Drug and Walmart. It certainly would have been good to hear about that earlier, but it appears that BIEL's new affiliation with E & E Communications has helped with the openness of issues. Just my opinion, but I hope this is a good sign for better visibility going forward.

That is a good positive perspective on things! The sell order was only in for a few minutes in both cases, so it does sound like that is progress (as compared with your lack of success trying this out a while back). Thanks and good luck.

FYI, The two 999,999 sells have been from me. They are at market order price of 0.00001 (Schwab does not allow a limit price lower than 0.0001, so I'm forced to enter as a market order). This is the only way that I can get rid of the shares that I have remaining in HESG so that I can write off the loss of this huge disappointment that I have been holding for over two years. After transaction fees, I'm left with a whopping $1.05 from the sale. I do wish you all good luck in the future with this stock! I just did not want to hold any longer.

It's been several months since I have last posted on this board, but I read messages everyday and have been a long term investor for over 2 years. First of all, a big "Thank You" to all of the regular posters that have worked hard to share useful and insightful information regularly. Great work!

I do want to share some product information that many may not be aware of. Tonight after ordering a replacement back pain Actipatch on Amazon for my daugther who suffers chronic hip arthritis pain from years of gymnastics, I noticed that Amazon does now carry an Actipatch Women's (and men's) Smart insole for foot and heel pain. It appears to be the PEMF hardware, encapsulated in a blue shoe insert (very similar to what I would expect a Dr. Scholls insert to look like). It is a 7-day continuous use product, so it must have the new shorter-life battery. Price is $29.95. This may be common knowledge to many investors, but I just wanted to post this to let everyone know that this product is now available. I will report back after my wife has used the insole to let you know her experience with it.

Thank you for passing that along yankee. I agree that was a very balanced, objective look at BIEL and helps to put things in perspective.

Thanks for making the contact and letting us know the response. Did they give any more definition to that statement? We all hope that is true of course. I do get skeptical of such statements considering Andrew's comments in his Aug. 9th Letter from the President where he stated "Either way, we are certain that FDA clearance is inevitable and close." I realize that BIEL can't control FDA's timetable on a decision, so they must be as frustrated as we investors are in the never-ending delays.

Good point Savannah. I work as a manager in a very large corporation, and we have unexpected delays and setbacks all the time! I continue to be very reassured by the progressive steps the BIEL is taking and remind myself that patience is the key here.

Just an FYI to all..... Kristen Jeffery is no longer the Administrative Manager point of contact in their Investor Relations department. Ben Fichter has taken her place. Ben was very responsive to an email inquiry that I made earlier in the week and he welcomes any investor questions. Good to see that they are trying to be very open and responsive in all areas. The email address is IR@bielcorp.com.

Thanks for the posting and information Canny Lad. Always good to hear feedback that investors have received from BIEL, and especially directly from Andy. To help promote the general level of content on this forum, I'd encourage you to be a regular contributor as well. You apparently have good insight and information to share, and timely inputs in this forum would be welcome. Sharing information several weeks after the fact loses some of the value in my opinion. Many of us do try to contribute what we can, and I would encourage you and other informed investors to input regularly as well. Thanks again.